Precision Therapeutics, Inc.

55 articles about Precision Therapeutics, Inc.

• Precision Therapeutics Making Rapid Progress with Both Personalized Medicine and Unique Medical Waste Disposal System

  8/7/2018

  ​CEOLive.TV released its second video interview [https://ceolive.tv/precision-therapeutics-aipt-gets-european-patent/] with Dr. Carl Schwartz, CEO of Precision Therapeutics Inc (NASDAQ:AIPT

• Precision Therapeutics, Inc. Cancer Vaccine Developer Treos Bio Opens U.S. Headquarters In San Francisco

  3/21/2017

• Precision Therapeutics, Inc. Transforms Into Helomics™ Corporation, Nabs $60 Million

  11/13/2014

• CEO Departs Pittsburgh-Based Cancer Diagnostics Firm Precision Therapeutics, Inc.

  10/7/2014

• Precision Therapeutics, Inc. Release: Manuscript Demonstrating Chemofx Is A Predictive Marker In Ovarian Cancer Published By The British Journal Of Cancer

  7/22/2014

• Precision Therapeutics, Inc. Supports The Annual National Ovarian Cancer Coalition (NOCC) Run/Walk To Break The Silence

  7/17/2014

• Precision Therapeutics, Inc. Release: Two Pivotal Manuscripts On ChemoFx Accepted For Publication

  6/26/2014

• Precision Therapeutics, Inc. Release: Data Demonstrating The Ability Of Chemofx® To Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior To Treatment Published ByThe American Journal Of Obstetrics And Gynecology

  2/24/2014

• Precision Therapeutics, Inc. Uses Automated Method To Extract RNA For Use In The GeneFx&#0174 Colon Signature

  12/16/2013

• Precision Therapeutics, Inc. Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer

  11/5/2013

• Precision Therapeutics, Inc. Presents Clinical Data Showing the ChemoFx® Drug Response Test Has Predictive Value in Recurrent Epithelial Ovarian Cancer

  11/5/2013

• Precision Therapeutics, Inc. Announces Unparalleled Results That Show Recurrent Ovarian Cancer Patients Live 65% Longer in Breakthrough Prospective Clinical Trial

  8/19/2013

• Precision Therapeutics, Inc. Release: ChemoFx® Chemoresponse Assay Identifies Platinum-Resistance in Primary Ovarian Cancer Patients

  7/8/2013

• Precision Therapeutics, Inc. to Present Clinical Data Showing Significant Association between ChemoFx® Results and Improved Outcomes in Recurrent Ovarian Cancer at the 2013 European Cancer Congress

  6/20/2013

• Precision Therapeutics, Inc. Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO

  5/9/2013

• Precision Therapeutics, Inc. Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO

  5/9/2013

• Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting

  5/6/2013

• Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting

  5/6/2013

• Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to Be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting

  5/6/2013

• Precision Therapeutics, Inc. Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer Using Personalized Chemotherapy Diagnostic ChemoFx®

  3/11/2013